Optimising pharmacological maintenance treatment for COPD in primary care

Primary Care Respiratory Journal

Volumn 20, Issue 1, 2011, Pages 33-45

  Jones, Rupert ^a   Østrem, Anders ^b  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

^b Gransdalen Legesenter   (Norway)

Author keywords

COPD; Diagnosis; Exacerbations; Guideline; Management; Primary care; Treatment

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID DERIVATIVE; FLUTICASONE; FORMOTEROL; INDACATEROL; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; ROFLUMILAST; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADD ON THERAPY; ANXIETY DISORDER; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DEPRESSION; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXERCISE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH EDUCATION; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MORTALITY; NAUSEA; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIMARY MEDICAL CARE; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SIDE EFFECT; SPIROMETRY; SURVIVAL RATE; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 80053053229     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.4104/pcrj.2010.00069     Document Type: Review

References (138)

1. Menezes AM, Perez-Padilla R, Hallal PC, et al. Worldwide burden of COPD in highand low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study. Int J Tuberc Lung Dis 2008;12(7):709-12.
2. Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006;61(12):1043-1047.http://dx.doi.org/10.1136/ thx.2006.064410
3. Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. Int J Tuberc Lung Dis 2008;12(7):703-08.
4. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27(2):397-412. http://dx.doi.org/10.1183/09031936.06.00025805
5. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. www.goldcopd.com. Accessed January 14, 2010.
6. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370(9589):765-773. http://dx.doi.org/10.1016/S0140-6736(07)61380-4
7. Nielsen R, Johannessen A, Benediktsdottir B, et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J 2009;34(4):850-857. http://dx.doi.org/10.1183/09031936.00166108
8. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000;117:5S-9S. http://dx.doi.org/10.1378/chest.117.2_suppl.5S
9. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3(11):e442 http://dx.doi.org/10.1371/journal.pmed.0030442
10. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294(10):1255-9.
11. Camilli AE, Burrows B, Knudson RJ, Lyle SK, Lebowitz MD. Longitudinal changes in forced expiratory volume in one second in adults. Effects of smoking and smoking cessation. Am Rev Respir Dis 1987;135(4):794-9.
12. Scanlon PD, Connett JE, Waller LA, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161(2):381-90.
13. Willemse BW, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004;23(3):464-76. http://dx.doi.org/10.1183/09031936.04.00012704
14. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89. http://dx.doi.org/10.1056/NEJMoa063070
15. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009;374(9696):1171-1178. http://dx.doi.org/10.1016/S0140-6736(09)61298-8
16. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009;10:59
17. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977;1(6077):1645-8.
18. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention. COPD 2008;5(4):235-56.
19. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003;41:46s-53s. http://dx.doi.org/10.1183/09031936.03.00078002
20. Beaucage F, Frémault A, Janssens W, Pottel H, Decramer M. FEV1 decline in COPD patients according to severity stages. Am J Respir Crit Care Med 2008;177:A401.
21. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272(19):1497-505.
22. Gorecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003;123:1916-23. http://dx.doi.org/10.1378/chest.123.6.1916
23. Stratelis G, Molstad S, Jakobsson P, Zetterstrom O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. Scand J Prim Health Care 2006;24:133-139. http://dx.doi.org/10.1080/02813430600819751
24. Kotz D, Wesseling G, Huibers MJ, van Schayck OC. Efficacy of confronting smokers with airflow limitation for smoking cessation. Eur Respir J 2009;33:754-62. http://dx.doi.org/10.1183/09031936.00116308
25. Yawn B, Mannino D, Littlejohn T, et al. Prevalence of COPD among symptomatic patients in a primary care setting. Curr Med Res Opin 2009;25(11):2671-7.
26. Bednarek M, Maciejewski J, Wozniak M, Kuca P, Zielinski J. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax 2008;63(5):402-07. http://dx.doi.org/10.1136/thx.2007.085456
27. Vandevoorde J, Verbanck S, Gijssels L, et al. Early detection of COPD: a case finding study in general practice. Respir Med 2007;101(3):525-30.
28. Tinkelman DG, Price D, Nordyke RJ, Halbert RJ. COPD screening efforts in primary care: what is the yield? Prim Care Resp J 2007;16(1):41-8. http://dx.doi.org/10.3132/pcrj.2007.00009
29. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma 2006;43(1):75-80. http://dx.doi.org/10.1080/02770900500448738
30. Kesten S, Chapman KR. Physician perceptions and management of COPD. Chest 1993;104(1):254-8.
31. Schermer TR, Smeele IJ, Thoonen BP, et al. Current clinical guideline definitions of airflow obstruction and COPD overdiagnosis in primary care. Eur Respir J 2008;32:945-52. http://dx.doi.org/10.1183/09031936.00170307
32. Barnes PJ. Mechanisms in COPD. Differences from asthma. Chest 2000;117(2):10S-14S. http://dx.doi.org/10.1378/chest.117.2_suppl.10S
33. Jeffery PK. Comparison of the structural and inflammatory features of COPD and asthma. Giles F Filley lecture. Chest 2000; 117(5):251S-260S. http://dx.doi.org/10.1378/chest.117.5_suppl_1.251S
34. Buist AS. Similarities and differences between asthma and chronic obstructive pulmonary disease: treatment and early outcomes. Eur Respir J Suppl 2003;39:30s-35s. http://dx.doi.org/10.1183/09031936.03.00404903
35. Welte T, Groneberg DA. Asthma and COPD. Exp Toxicol Pathol 2006;57 Suppl 2:35-40. http://dx.doi.org/10.1016/j.etp.2006.02.004
36. Chang J, Mosenifar Z. Differentiating COPD from asthma in clinical practice. J Intensive Care Med 2007;22(5):300-09. http://dx.doi.org/10.1177/0885066607304445
37. Brusasco V. Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur Respir Rev 2006;15(99):32-6. http://dx.doi.org/10.1183/09059180.00009902
38. Fletcher CM, Elmes PC, Fairbain AS. The significance of respiratory symptoms and diagnosis of chronic bronchitis in working population. BMJ 1959;2:257-66.
39. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009;180(12):1189-95. http://dx.doi.org/10.1164/rccm.200902-0271OC
40. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009;374:704-711.http://dx.doi.org/10.1016/S0140-6736(09)61301-5
41. Celli BR, MacNee W, and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46. http://dx.doi.org/10.1183/09031936.04.00014304
42. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease -2007 update. Can Respir J 2007;14 Suppl B:5B-32B.
43. National Board of Health and Welfare. The National Board of Health and Welfare Guidelines for Asthma and COPD 2004 (in Swedish). Socialstyrelsen 2004;
44. National Institute for Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. Clinical guideline 12. Thorax 2004;59 (Suppl I):i1-i232
45. Bellamy D, Bouchard J, Henrichsen S, et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Resp J 2006;15(1):48-57. http://dx.doi.org/10.1016/j.pcrj.2005.11.003
46. Levy ML, Fletcher M, Price DB, Hausen T, Halbert RJ, Yawn BP. International Primary Care Respiratory Group (IPCRG) Guidelines: diagnosis of respiratory diseases in primary care. Prim Care Resp J 2006;15(1):20-34. http://dx.doi.org/10.1016/j.pcrj.2005.10.004
47. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290(17):2301-2312.
48. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004;125(1):249-259. http://dx.doi.org/10.1378/chest.125.1.249
49. Vincken W. Bronchodilator treatment of stable COPD: long-acting anticholinergics. Eur Respir Rev 2005;14:23-31. http://dx.doi.org/10.1183/09058180.05.00009403
50. Campbell M, Eliraz A, Johansson G, et al. Formoterol for maintenance and asneeded treatment of chronic obstructive pulmonary disease. Respir Med 2005;99(12):1511-1120. http://dx.doi.org/ 10.1016/j.rmed.2005.08.016
51. Derom E, Strandgarden K, Schelfhout V, Borgstrom L, Pauwels R. Lung deposition and efficacy of inhaled formoterol in patients with moderate to severe COPD. Respir Med 2007;101(9):1931-1941. http://dx.doi.org/ 10.1016/j.rmed.2007.04.013
52. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115(4):957-65. http://dx.doi.org/10.1378/chest.115.4.957
53. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 1997;112(2):336-40. http://dx.doi.org/10.1378/chest.112.2.336
54. Cote C, Pearle JL, Sharafkhaneh A, Spangenthal S. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther 2009;22(1):44-9. http://dx.doi.org/10.1016/j.pupt.2008.11.010
55. Kottakis J, Cioppa GD, Creemers J, et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 2002;9(2):107-15.
56. Briggs DD, Jr., Covelli H, Lapidus R, Bhattycharya S, Kesten S, Cassino C. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther 2005;18(6):397-404. http://dx.doi.org/10.1016/j.pupt.2005.02.013
57. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58(5):399-404.
58. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24. http://dx.doi.org/10.1183/09031936.02.00269802
59. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur espir J 2005;26(2):214-22. http://dx.doi.org/10.1183/09031936.05.00140404
60. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in atients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-16. http://dx.doi.org/10.1183/09031936.02.00238702
61. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The revention of chronic obstructive pulmonary disease exacerbations by almeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care ed 2008;177(1):19-26. http://dx.doi.org/10.1164/rccm.200707-973OC
62. Decramer M. Tiotropium as essential maintenance therapy in COPD. Eur Respir Rev 2006;15(99):51-7. http://dx.doi.org/10.1183/09059180.00009906
63. Welte T. Optimising treatment for COPD--new strategies for combination therapy. nt J Clin Pract 2009;63(8):1136-49. http://dx.doi.org/10.1111/j.1742-1241.2009.02139.x
64. Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment f COPD: effects on lung function. COPD 2009;6(5):404-415.
65. Cazzola M, Dahl R. Inhaled combination therapy with long-acting beta 2-agonists nd corticosteroids in stable COPD. Chest 2004;126(1):220-237. http/dx.doi.org/10.1378/chest.126.1.220
66. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-19. http://dx.doi.org/10.1183/09031936.03.00027003
67. Suissa S, McGhan R, Niewoehner D, Make B. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007;4(7):535-42. http://dx.doi.org/10.1513/pats.200701-024FM
68. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined longacting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest 2009;136(4):1029-38. http://dx.doi.org/10.1378/chest.09-0821
69. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009;169(3):219-29. http://dx.doi.org/10.1001/archinternmed.2008.550
70. Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(20):2407-16.
71. Sobieraj DM, White CM, Coleman CI. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Clin Ther 2008;30(8):1416-25. http://dx.doi.org/10.1016/j.clinthera.2008.08.004
72. Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176(2):162-6. http://dx.doi.org/10.1164/rccm.200611-1630OC
73. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34(3):641-7. http://dx.doi.org/10.1183/09031936.00193908
74. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a metaanalysis of individual patient data. Lancet 2009; 374(9691):712-719. http://dx.doi.org/10.1016/S0140-6736(09)61250-2
75. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of triple therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63(7):592-8. http://dx.doi.org/10.1136/thx.2007.087213
76. Troosters T, Celli B, Kesten S, et al. Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial. Eur Respir J 2009; 34(Suppl 53):675S.
77. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(8):741-50. http://dx.doi.org/10.1164/rccm.200904-0492OC
78. Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids. Respirology 2006;11(5):598-602.
79. Siafakas NM, Vermeire P, Pride NB, Paoletti P. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398-420.
80. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006;11(5):603-10.
81. Glaab T, Banik N, Rutschmann OT, Wencker M. National survey of guidelinecompliant COPD management among pneumologists and primary care physicians. COPD 2006;3(3):141-8.
82. Rutschmann OT, Janssens JP, Vermeulen B, Sarasin FP. Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med 2004;98(10):932-7. http://dx.doi.org/10.1016/j.rmed.2004.03.018
83. Jones RC, Dickson-Spillmann M, Mather MJ, Marks D, Shackell BS. Accuracy of diagnostic registers and management of chronic obstructive pulmonary disease: the Devon primary care audit. Respir Res 2008;9:62. http://dx.doi.org/10.1186/1465-9921-9-62
84. Bourbeau J, Sebaldt RJ, Day A, et al. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study. Can Respir J 2008;15(1):13-19.
85. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15):1543-1554. http://dx.doi.org/10.1056/NEJMoa0805800
86. Haahtela T, Tuomisto LE, Pietinalho A, et al. A 10 year asthma programme in Finland: major change for the better. Thorax 2006;61(8):663-670. http://dx.doi.org/10.1136/thx.2005.055699
87. Price D, Freeman D, Kaplan A, Ostrem A, Reid J, Molen T. Progressive breathlessness in COPD - the role of hyperinflation and its pharmacological management. Prim Care Resp J 2005;14(6):285-293. http://dx.doi.org/10.1016/j.pcrj.2005.08.005
88. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008;178(4):332-338. http://dx.doi.org/10.1164/rccm.200712-1869OC
89. Miravitlles M, Anzueto A. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J Chron Obstruct Pulmon Dis 2009;4:185-201.
90. Morice A, Celli B, Kesten S, et al. COPD patients under 50 years of age:4-year follow-up in the UPLIFT trial. Eur Respir J 2009;34(Suppl 53): 674S.
91. Troosters T, Celli B, Burkhart SD, et al. Effectiveness of tiotropium as first maintenance drug in patients with COPD. Secondary analysis of the UPLIFT trial. Am J Respir Crit Care Med 2009;179:A2467. http://dx.doi.org/10.1016/S0954-6111(06)80166-6
92. Jones PW, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. Respir Med 1991;85(Suppl B):25-31. http://dx.doi.org/10.1016/S0954-6111(06)80166-6
93. Novartis. Novartis receives approval in the European Union for Onbrez Breezhaler, a new once-daily bronchodilator for patients with COPD. www.novartis.com. Accessed January 14, 2010.
94. Schering Plough. Product pipeline. www.merck.com. Accessed January 14, 2010.
95. Chiesi R&D pipeline 2009. www.chiesigroup.com. Accessed January 14, 2010.
96. Nycomed. Pipeline overview. Key pipeline products. www.nycomed.com. Accessed January 14, 2010.
97. Almirall. Product development pipeline. www.almirall.com. Accessed January 14, 2010.
98. Mullard A. GSK drops daratropium in favour of GSK573719 for COPD. www.scripnews.com. Accessed January 14, 2010.
99. Glaxo SmithKline. Product development pipeline. www.gsk.com. Accessed January 14, 2010.
100. Novartis. Clinical pipeline. Planned filings. www.novartis.com. Accessed January 14, 2010.
101. A dose-finding study evaluating safety and efficacy in patients with chronic obstructive pulmonary disease (NCT00403286). www.clinicaltrials.gov. Accessed January 14, 2010.
102. Combination of orally inhaled BI1744Cl/tiotropium bromide in patients with chronic obstructive pulmonary disease (COPD) (NCT00696020). www.clinicaltrials.gov. Accessed January 14, 2010.
103. Efficacy and safety of 4 weeks treatment with inhaled BI 1744 CL in patients with COPD (NCT00452400). www.clinicaltrials.gov. Accessed January 14, 2010.
104. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008;102(7):1033-44. http://dx.doi.org/10.1016/j.rmed.2008.02.001
105. Barnes P, Pocock S, Magnussen H, et al. Indacaterol dose selection: utilising an adaptive seamless design in a clinical study in COPD. Eur Respir J 2009;34(Suppl 53): 778s.
106. Fogarty C, Hebert J, Iqbal A, Owen R, Higgins M, Kramer B. Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium. Eur Respir J 2009; 34 (Suppl 53):345s.
107. Yorgancioglu A, Mahler, D, Iqbal A, Owen R, Higgins M, Kramer B. Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium. Eur Respir J 2009;34 (Suppl 53):346s.
108. Mahler D, Palange P, Iqbal A, Owen R, Higgins M, Kramer B. Indacaterol once-daily improves dyspnoea in COPD patients: a 26-week placebo-controlled study with open-label tiotropium comparison. Eur Respir J 2009;34(Suppl 53):779s.
109. Dahl R, Kolman P, Jack D, et al. Bronchodilator therapy with indacaterol once-daily in COPD: a 52-week comparison with formoterol. Eur Respir J 2009;34(Suppl 53):776s-777s.
110. Nonikov V, Verkindre C, Jack D, et al. Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for). Eur Respir J 2009;34(Suppl 53):345s.
111. Magnussen H, Paggiaro P, Jack D, Owen R, Higgins M, Kramer B. Indacaterol oncedaily improves health-related quality of life (HRQOL) in COPD patients: a 52-week study. Eur Respir J 2009;34(Suppl 53):344s.
112. Buhl R, Pieters W, Jack D, Owen R, Kramer B, Higgins M. Indacaterol once-daily improves dyspnoea and BODE index in COPD patients: a 52-week study. Eur Respir J 2009;34(Suppl 53):345s-346s.
113. Chung F, Kornmann O, Jack D, Owen R, Kramer B, Higgins M. Safety and tolerability of indacaterol over 52 weeks of treatment in COPD. Eur Respir J 2009;34(Suppl 53):778s-779s.
114. Worth H, Kleerup E, Iqbal A, Owen R, Kramer B, Higgins M. Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study. Eur Respir J 2009;34(Suppl 53):346s.
115. Lipworth BJ. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005;365(9454):167-175. http://dx.doi.org/10.1016/S0140-6736(05)17708-3
116. European Medicines Agency and Committee for Medicinal Products for Human Use. Summary of opinion (initial authorisation). Daxas. Roflumilast. European Medicines Agency. Available from: http://www.ema.europa.eu. Accessed 12 May 2010.
117. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374(9691):685-694. http://dx.doi.org/10.1016/S0140-6736(09)61255-1
118. Hodder R, Kesten S, Menjoge S, Viel K. Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids. Int J Chron Obstruct Pulmon Dis 2007;2(2):157-167.
119. Tashkin DP, Celli B, Kesten S, Lystig T, Mehra S, Decramer M. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 2010;35:287-294. http://dx.doi.org/10.1183/09031936.00082909
120. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbroker D, Bethke TD. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005;366(9485):563-571. http://dx.doi.org/10.1016/S0140-6736(05)67100-0
121. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-tosevere chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374(9691):695-703. http://dx.doi.org/10.1016/S0140-6736(09)61252-6
122. Rennard S, Donohue J, Bateman E, Gross N, Garcia-Gil E, Caracta C. ACCLAIM/COPD II: Efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist in COPD patients, a Phase III study. Eur Respir J 2009;34(Suppl 53):777s.
123. Jones P, Agusti J, Chanez P, et al. Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD. Eur Respir J 2009;34(Suppl 53): 345s.
124. Vestbo J, Vogelmeier C, Creemers J, Ribera A, Garcia-Gil E. Rate of onset of action of aclidinium bromide, a novel, long-acting muscarinic antagonist. Eur Respir J 2009;34 (Suppl 53):779s.
125. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146(8):545-55.
126. de Marco R, Accordini S, Cerveri I, et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004;59(2):120-5. http://dx.doi.org/10.1136/thorax.2003.011163
127. Calverley PM. COPD: early detection and intervention. Chest 2000;117(5 Suppl 2):365S-371S. http://dx.doi.org/10.1378/chest.117.5_suppl_2.365S
128. Miravitlles M, De la RC, Naberan K, Lamban M, Gobartt E, Martin A, Chapman KR. Attitudes toward the diagnosis of chronic obstructive pulmonary disease in primary care. Arch Bronconeumol 2006;42(1):3-8.http://dx.doi.org/10.1016/S1579-2129(06)60106-7
129. van Schayck CP, Loozen JMC, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. Br Med J 2002;324:1370-4.
130. Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest 2004;125(4):1394-1399. http://dx.doi.org/10.1378/chest.125.4.1394
131. Kaufmann M, Hartl S, Geyer K, Breyer MK, Burghuber OC. Measuring FEV(6) for detecting early airway obstruction in the primary care setting. Quality and utility of the new PiKo-6 device. Respiration 2009;78(2):161-167. http://dx.doi.org/10.1159/000197466
132. Price D, Crockett A, Arne M, et al. Spirometry in primary care case-identification, diagnosis and management of COPD. Prim Care Resp J 2009;18(3):216-223. http://dx.doi.org/10.4104/pcrj.2009.00055
133. George J, Kong DC, Thoman R, Stewart K. Factors associated with medication nonadherence in patients with COPD. Chest 2005;128(5):3198-3204. http://dx.doi.org/10.1378/chest.128.5.3198
134. George J, Kong DC, Stewart K. Adherence to disease management programs in patients with COPD. Int J Chron Obstruct Pulmon Dis 2007;2(3):253-262.
135. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009;64(11):939-943. http://dx.doi.org/10.1136/thx.2009.113662
136. Celli B. Chronic obstructive pulmonary disease. From unjustified nihilism to evidence-based optimism. Proc Am Thorac Soc 2006;3:58-65. http://dx.doi.org/10.1513/pats.200510-111JH
137. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009;180(1):3-10. http://dx.doi.org/10.1164/rccm.200901-0047OC
138. Barnes PJ, Drazen JM, Rennard SI, Thomson NC. Asthma and COPD, second edition: Basic mechanisms and clinical management.: Academic Press, 2008